Eton Pharmaceuticals Enters Material Definitive Agreement
Ticker: ETON · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1710340
Sentiment: neutral
Topics: material-agreement
Related Tickers: ETON
TL;DR
ETON just signed a big deal, details TBD.
AI Summary
Eton Pharmaceuticals, Inc. announced on December 10, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures.
Why It Matters
This filing indicates a significant new development for Eton Pharmaceuticals, potentially impacting its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Eton Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the other party to the agreement.
What is the effective date of this material definitive agreement?
The earliest event reported is December 10, 2024.
Are there any financial terms or obligations associated with this agreement disclosed in the filing?
No financial terms or obligations are disclosed in this filing.
Does this agreement represent an acquisition, partnership, or other strategic move for Eton Pharmaceuticals?
The filing does not provide enough information to determine the specific type of strategic move.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-12 16:30:51
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $12.00 — "Common Stock") at an offering price of $12.00 per Share. There was no placement agent
- $7.0 million — ny from the Offering were approximately $7.0 million before deducting related offering expen
Filing Documents
- eton20241211_8k.htm (8-K) — 27KB
- ex_756274.htm (EX-10.1) — 71KB
- 0001437749-24-037367.txt ( ) — 243KB
- eton-20241210.xsd (EX-101.SCH) — 3KB
- eton-20241210_def.xml (EX-101.DEF) — 11KB
- eton-20241210_lab.xml (EX-101.LAB) — 15KB
- eton-20241210_pre.xml (EX-101.PRE) — 11KB
- eton20241211_8k_htm.xml (XML) — 3KB
01: Entry into a Material Definitive Agreement
Item 1.01: Entry into a Material Definitive Agreement On December 10, 2024, Eton Pharmaceuticals, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Investor"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the "Offering"), 583,334 shares (the "Shares") of common stock, par value $0.001 per share, of the Company ("Common Stock") at an offering price of $12.00 per Share. There was no placement agent or underwriter in the Offering. The gross proceeds to the Company from the Offering were approximately $7.0 million before deducting related offering expenses. The Company intends to use the proceeds from this offering, together with existing cash and cash equivalents, for funding acquisition opportunities for products or product candidates when and if they arise. The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Investor and customary indemnification rights and obligations of the parties. The Shares were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-271196), which was filed with the Securities and Exchange Commission (the "Commission") on April 7, 2023 and was declared effective by the Commission on May 2, 2023 (the "Registration Statement"). A copy of the form of purchase agreement is attached as Exhibit 10.1. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 10.1 Form of Purchase Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4